Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Serine/threonine-protein kinase mTOR | ||
| Ligand | BDBM50433034 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_955789 (CHEMBL2379606) | ||
| Ki | 9.1±n/a nM | ||
| Citation |  Cheng, H; Hoffman, JE; Le, PT; Pairish, M; Kania, R; Farrell, W; Bagrodia, S; Yuan, J; Sun, S; Zhang, E; Xiang, C; Dalvie, D; Rahavendran, SV Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. Bioorg Med Chem Lett23:2787-92 (2013) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Serine/threonine-protein kinase mTOR | |||
| Name: | Serine/threonine-protein kinase mTOR | ||
| Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
| Type: | Rapamycin target protein | ||
| Mol. Mass.: | 288917.12 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | P42345 | ||
| Residue: | 2549 | ||
| Sequence: |
| ||
| BDBM50433034 | |||
| n/a | |||
| Name | BDBM50433034 | ||
| Synonyms: | CHEMBL2375953 | US8633204, 310 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C25H26N6O3 | ||
| Mol. Mass. | 458.5123 | ||
| SMILES | Cc1nc(N)nc2n([C@H]3CC[C@@H](CC3)OCC(N)=O)c(=O)c(cc12)-c1cnc2ccccc2c1 |r,wU:11.14,wD:8.7,(66.59,-45.15,;66.6,-46.69,;65.27,-47.46,;65.26,-49,;63.93,-49.77,;66.6,-49.77,;67.93,-49.01,;69.27,-49.78,;69.26,-51.32,;67.92,-52.08,;67.91,-53.62,;69.24,-54.4,;70.58,-53.63,;70.59,-52.09,;69.23,-55.94,;67.89,-56.7,;66.56,-55.92,;65.22,-56.68,;66.57,-54.38,;70.62,-49.01,;71.95,-49.78,;70.62,-47.46,;69.27,-46.67,;67.93,-47.45,;71.96,-46.7,;73.29,-47.47,;74.62,-46.71,;74.62,-45.17,;75.95,-44.41,;75.96,-42.86,;74.62,-42.09,;73.29,-42.86,;73.29,-44.39,;71.96,-45.16,)| | ||
| Structure | 
| ||